123 related articles for article (PubMed ID: 7778023)
1. Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer.
Yamashita J; Ogawa M; Sakai K
Surgery; 1995 Jun; 117(6):601-8. PubMed ID: 7778023
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
Kim SJ; Shiba E; Kobayashi T; Yayoi E; Furukawa J; Takatsuka Y; Shin E; Koyama H; Inaji H; Takai S
Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968
[TBL] [Abstract][Full Text] [Related]
3. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
Jänicke F; Prechtl A; Thomssen C; Harbeck N; Meisner C; Untch M; Sweep CG; Selbmann HK; Graeff H; Schmitt M;
J Natl Cancer Inst; 2001 Jun; 93(12):913-20. PubMed ID: 11416112
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer.
Foekens JA; Ries C; Look MP; Gippner-Steppert C; Klijn JG; Jochum M
Cancer Res; 2003 Jan; 63(2):337-41. PubMed ID: 12543785
[TBL] [Abstract][Full Text] [Related]
5. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
Harbeck N; Kates RE; Schmitt M
J Clin Oncol; 2002 Feb; 20(4):1000-7. PubMed ID: 11844823
[TBL] [Abstract][Full Text] [Related]
7. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
Harbeck N; Schmitt M; Meisner C; Friedel C; Untch M; Schmidt M; Sweep CG; Lisboa BW; Lux MP; Beck T; Hasmüller S; Kiechle M; Jänicke F; Thomssen C;
Eur J Cancer; 2013 May; 49(8):1825-35. PubMed ID: 23490655
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
Harbeck N; Alt U; Berger U; Krüger A; Thomssen C; Jänicke F; Höfler H; Kates RE; Schmitt M
Clin Cancer Res; 2001 Sep; 7(9):2757-64. PubMed ID: 11555589
[TBL] [Abstract][Full Text] [Related]
9. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
[TBL] [Abstract][Full Text] [Related]
10. Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer.
Yamashita J; Ogawa M; Yamashita S; Nakashima Y; Saishoji T; Nomura K; Inada K; Kawano I
Br J Cancer; 1993 Sep; 68(3):524-9. PubMed ID: 8394731
[TBL] [Abstract][Full Text] [Related]
11. A nomogram to predict individual prognosis in node-negative breast carcinoma.
Mazouni C; Spyratos F; Romain S; Fina F; Bonnier P; Ouafik LH; Martin PM
Eur J Cancer; 2012 Nov; 48(16):2954-61. PubMed ID: 22658808
[TBL] [Abstract][Full Text] [Related]
12. Extracapsular axillary node extension in patients receiving adjuvant systemic therapy: an indication for radiotherapy?
Fisher BJ; Perera FE; Cooke AL; Opeitum A; Dar AR; Venkatesan VM; Stitt L; Radwan JS
Int J Radiat Oncol Biol Phys; 1997 Jun; 38(3):551-9. PubMed ID: 9231679
[TBL] [Abstract][Full Text] [Related]
13. [u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast].
Harbeck N; Thomssen C
Zentralbl Gynakol; 2003 Sep; 125(9):362-7. PubMed ID: 14569518
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant tamoxifen alone: patterns of recurrence.
Fisher BJ; Perera FE; Cooke AL; Opeitum A; Stitt L
Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):117-23. PubMed ID: 9747828
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.
Harbeck N; Schmitt M; Kates RE; Kiechle M; Zemzoum I; Jänicke F; Thomssen C
Clin Breast Cancer; 2002 Aug; 3(3):196-200. PubMed ID: 12196277
[TBL] [Abstract][Full Text] [Related]
16. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
Zemzoum I; Kates RE; Ross JS; Dettmar P; Dutta M; Henrichs C; Yurdseven S; Höfler H; Kiechle M; Schmitt M; Harbeck N
J Clin Oncol; 2003 Mar; 21(6):1022-8. PubMed ID: 12637466
[TBL] [Abstract][Full Text] [Related]
17. Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
Jevrić M; Matić IZ; Krivokuća A; Đorđić Crnogorac M; Besu I; Damjanović A; Branković-Magić M; Milovanović Z; Gavrilović D; Susnjar S; Kisić Tepavčević D; Stanojković T
BMC Cancer; 2019 Jan; 19(1):71. PubMed ID: 30646864
[TBL] [Abstract][Full Text] [Related]
18. A prospective study on the prognostic significance of urokinase-type plasminogen activator levels in breast cancer tissue.
Shiba E; Kim SJ; Taguchi T; Izukura M; Kobayashi T; Furukawa J; Yayoi E; Shin E; Takatsuka Y; Koyama H; Takai S
J Cancer Res Clin Oncol; 1997; 123(10):555-9. PubMed ID: 9393589
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma.
Li HC; Cao DC; Liu Y; Hou YF; Wu J; Lu JS; Di GH; Liu G; Li FM; Ou ZL; Jie C; Shen ZZ; Shao ZM
Breast Cancer Res Treat; 2004 Nov; 88(1):75-85. PubMed ID: 15538048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]